Mary W Redman

10PUBLICATIONS
118CO-AUTHORS
Predictive and prognostic markersTumour immunologyMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Jun 04, 2025
Elevated ctDNA Tumor Fraction Is Associated with Improved Mutation Detection but Worse Overall Survival in Advanced Non-Small Cell Lung Cancer: A Lung-MAP Study.

Philip C Mack, Mary W Redman, Hanna Tukachinsky

|Apr 10, 2024
A process to reanalyze clinical DNA sequencing data for biomarker matching in the Lung-MAP Master Protocol.

Joel W Neal, Katherine Minichiello, Ryan Brennick

|Jan 26, 2024
Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial.

Edwin Roger Parra, Jiexin Zhang, Dzifa Yawa Duose

|Sep 07, 2023
Representativeness of Patients Enrolled in the Lung Cancer Master Protocol (Lung-MAP).

Riha Vaidya, Joseph M Unger, Lu Qian

|Jun 09, 2023
Elevated EVL Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent Adenomas.

Ming Yu, Kelly T Carter, Kelsey K Baker

|May 26, 2023
Phase II Study of Docetaxel and Trametinib in Patients with KRAS Mutation Positive Recurrent Non-Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042).

Shirish M Gadgeel, Jieling Miao, Jonathan W Riess

Pageof 2

Frequent Collaborators

7 joint publications

Roy S Herbst

6 joint publications

Karen Kelly

6 joint publications

David R Gandara

5 joint publications

Karen L Reckamp